Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim
| Autor: | Weijia Wang, Sanjeev Balu, Ali McBride, Karen MacDonald, Kim Campbell, Ivo Abraham |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Filgrastim Cost-Benefit Analysis Neutropenia Polyethylene Glycols Hematologic Agents Neoplasms medicine Humans Economic analysis Chemotherapy-Induced Febrile Neutropenia Intensive care medicine Biosimilar Pharmaceuticals Cost efficiency business.industry Health Policy Biosimilar medicine.disease United States Models Economic Expanded access Economic model business Febrile neutropenia Pegfilgrastim medicine.drug |
| Zdroj: | Journal of Medical Economics. 23:856-863 |
| ISSN: | 1941-837X 1369-6998 |
| Popis: | Aims: For this economic analysis, we aimed to model: (1) the cost-efficiency of prophylaxis with biosimilar pegfilgrastim-bmez for chemotherapy-induced (febrile) neutropenia (CIN/FN) compared to re... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|